| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $0 ) |
| | 2026 | 2025 | PHUSIS THERAPEUTICS, INC. | 6019 FOLSOM DR | LA JOLLA | CA | 92037-6712 | SAN DIEGO | USA | R44CA306740 | Clinical evaluation of a novel AKT/PDK1 inhibitor, PHT-427, for the treatment of multi-field actinitc keratoses | 000 | 1 | NIH | 6/10/2026 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $1,868,357 ) |
| | 2025 | 2025 | PHUSIS THERAPEUTICS, INC. | 6019 FOLSOM DR | LA JOLLA | CA | 92037-6712 | SAN DIEGO | USA | R44CA306740 | Clinical evaluation of a novel AKT/PDK1 inhibitor, PHT-427, for the treatment of multi-field actinitc keratoses | 000 | 1 | NIH | 9/8/2025 | $2,085,765 |
| | 2025 | 2022 | PHUSIS THERAPEUTICS, INC. | 6019 FOLSOM DR | LA JOLLA | CA | 92037-6712 | SAN DIEGO | USA | R01CA216424 | Inhibiting Multi-Functional ALDOA for Cancer Therapy | 000 | 5 | NIH | 9/12/2025 | -$217,408 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | PHUSIS THERAPEUTICS, INC. | 6019 FOLSOM DR | LA JOLLA | CA | 92037-6712 | SAN DIEGO | USA | R01CA216424 | Inhibiting Multi-Functional ALDOA for Cancer Therapy | 001 | 5 | NIH | 8/12/2024 | $0 |
| | 2024 | 2022 | PHUSIS THERAPEUTICS INC | 6019 FOLSOM DR | LA JOLLA | CA | 92037-6712 | SAN DIEGO | USA | R01CA216424 | Inhibiting Multi-Functional ALDOA for Cancer Therapy | 000 | 5 | NIH | 10/25/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = -$29,460 ) |
| | 2023 | 2022 | PHUSIS THERAPEUTICS INC | 6019 FOLSOM DR | LA JOLLA | CA | 92037-6712 | SAN DIEGO | USA | R01CA216424 | Inhibiting Multi-Functional ALDOA for Cancer Therapy | 001 | 5 | NIH | 8/28/2023 | $0 |
| | 2023 | 2021 | PHUSIS THERAPEUTICS, INC. | 6019 FOLSOM DR | LA JOLLA | CA | 92037-6712 | SAN DIEGO | USA | R21CA244691 | Targeting ERK5 for Colorectal Cancer Therapy | 000 | 2 | NIH | 5/1/2023 | -$29,460 |
| | 2023 | 2021 | PHUSIS THERAPEUTICS INC | 6019 FOLSOM DR | LA JOLLA | CA | 92037-6712 | SAN DIEGO | USA | R01CA216424 | Inhibiting Multi-Functional ALDOA for Cancer Therapy | 000 | 4 | NIH | 8/28/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $936,468 ) |
| | 2022 | 2022 | PHUSIS THERAPEUTICS, INC. | 6019 FOLSOM DR | LA JOLLA | CA | 92037-6712 | SAN DIEGO | USA | R01CA216424 | Inhibiting Multi-Functional ALDOA for Cancer Therapy | 002 | 5 | NIH | 8/19/2022 | $498,144 |
| | 2022 | 2021 | PHUSIS THERAPEUTICS INC | 6019 FOLSOM DR | LA JOLLA | CA | 92037-6712 | SAN DIEGO | USA | R01CA216424 | Inhibiting Multi-Functional ALDOA for Cancer Therapy | 001 | 4 | NIH | 10/29/2021 | $282,172 |
| | 2022 | 2021 | PHUSIS THERAPEUTICS INC | 6019 FOLSOM DR | LA JOLLA | CA | 92037-6712 | SAN DIEGO | USA | R21CA244691 | Targeting ERK5 for Colorectal Cancer Therapy | 001 | 2 | NIH | 10/21/2021 | $156,152 |
|
| Issue Date FY: 2021 ( Subtotal = $674,056 ) |
| | 2021 | 2021 | PHUSIS THERAPEUTICS, INC. | 6019 FOLSOM DR | LA JOLLA | CA | 92037-6712 | SAN DIEGO | USA | R01CA216424 | Inhibiting Multi-Functional ALDOA for Cancer Therapy | 001 | 4 | NIH | 9/24/2021 | $504,587 |
| | 2021 | 2021 | PHUSIS THERAPEUTICS, INC. | 6019 FOLSOM DR | LA JOLLA | CA | 92037-6712 | SAN DIEGO | USA | R21CA244691 | Targeting ERK5 for Colorectal Cancer Therapy | 001 | 2 | NIH | 9/24/2021 | $169,469 |
|
| Issue Date FY: 2014 ( Subtotal = $225,000 ) |
| | 2014 | 2014 | PHUSIS THERAPEUTICS INC | 7000 FANNIN STREET | HOUSTON | TX | 77030 | HARRIS | USA | R43CA186292 | Inhibiting PLEKHA7 for mutant KRAS therapy | 000 | 1 | NIH | 7/15/2014 | $225,000 |
|
| Issue Date FY: 2013 ( Subtotal = $287,434 ) |
| | 2013 | 2013 | PHUSIS THERAPEUTICS INC | 7000 FANNIN STREET | HOUSTON | TX | 77030 | HARRIS | USA | R43CA171345 | TARGETING MUTANT KRAS FOR CANCER THERAPY | 000 | 1 | NIH | 8/1/2013 | $287,434 |
|
|
